Purpose: To investigate the effects of the pretreatment neutrophil-to-lymphocyte ratio (N/L) on non-human papilloma virus (HPV)-related oropharyngeal cancer.
Materials and methods: N/L was calculated by dividing the neutrophil count by the lymphocyte count. Survival outcomes were estimated using the Kaplan-Meier method and compared by the log-rank test. Univariate and multivariate analyses were performed to evaluate the prognostic impact of N/L and other clinical factors on survival outcomes. High/low N/L groups were defined as > 4.7 and ≤4.7, respectively.
Results: Data of 57 consecutive patients with non-HPV-related oropharyngeal cancer were analyzed. The 3-year disease-free survival was 79 versus 36.9% in favor of the low N/L group (p = 0.04). The 5-year overall survival was 71.6 versus 53.3% in the low N/L and high N/L group, respectively (p = 0.07).
Conclusion: N/L could play an important role in non-HPV-related oropharyngeal cancer progression and indicate prognosis.
Keywords: Chemotherapy; Human papilloma virus; Neutrophil/lymphocyte ratio; Oropharyngeal cancer; Prognosis; Radiotherapy; Recurrence; Survival.
© 2018 S. Karger AG, Basel.